2-Pyridin-2-yl-1H-benzoimidazole-5-carboxamidine | 200112-19-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-Pyridin-2-yl-1H-benzoimidazole-5-carboxamidine
• 英文别名: 2-pyridin-2-yl-1H-benzimidazole-6-carboximidamide；2-pyridin-2-yl-3H-benzimidazole-5-carboximidamide
• CAS: 200112-19-2
• 化学式: C₁₃H₁₁N₅
• 分子量: 237.264
• InChiKey: RVIFTTGMSLOWED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  91.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  吡啶-2-甲醛 、 3,4-二氨基苯甲脒 在 对苯醌 作用下， 以 乙醇 为溶剂， 生成 2-Pyridin-2-yl-1H-benzoimidazole-5-carboxamidine
  参考文献：
  名称：

  Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation

  摘要：

  Inhibition of coagulation proteases such as thrombin, fXa, and fVIIa has been a focus of ongoing research to produce safe and effective antithrombotic agents. Herein, we describe a unique zinc-mediated chelation strategy to streamline the discovery of potert inhibitors of fIIa, fXa, and fVIIa. SAR studies that led to the development of selective inhibitors of fXa will also be detailed. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.10.023

文献信息

• METAL MEDIATED SERINE PROTEASE INHIBITORS
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：EP0943008A1

  公开（公告）日：1999-09-22
• MASP-2 INHIBITORS AND METHODS OF USE
  申请人：Omeros Corporation

  公开号：EP3802489A2

  公开（公告）日：2021-04-14
• Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome
  申请人：Omeros Corporation

  公开号：US20210292436A1

  公开（公告）日：2021-09-23

  In one aspect, the invention provides methods for treating, inhibiting, alleviating, or preventing acute respiratory distress syndrome, pneumonia, or some other pulmonary or other manifestation of coronavirus infection, such as thrombosis, in a mammalian subject infected with coronavirus, such as SARS-CoV-2. The methods comprise the step of administering to a subject infected with coronavirus an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In one embodiment, the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent is a small molecule MASP-2 inhibitory compound. In one embodiment, the subject is a human subject suffering from COVID-19-induced acute respiratory distress syndrome (ARDS) and requires supplemental oxygen prior to treatment and the MASP-2 inhibitory agent is administered in an amount sufficient to discontinue the need for supplemental oxygen.
• US6150379A
  申请人：——

  公开号：US6150379A

  公开（公告）日：2000-11-21
• US6255091B1
  申请人：——

  公开号：US6255091B1

  公开（公告）日：2001-07-03